首页> 外文期刊>Diabetes care >Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators.
【24h】

Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators.

机译:强化血糖控制对2型糖尿病患者微量白蛋白尿的影响。在2型糖尿病可行性试验研究人员中进行血糖控制和并发症的退伍军人事务合作研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Microalbuminuria can reflect the progress of microvascular complications and may be predictive of macrovascular disease in type 2 diabetes. The effect of intensive glycemic control on microalbuminuria in patients in the U.S. who have had type 2 diabetes for several years has not previously been evaluated. RESEARCH DESIGN AND METHODS: We randomly assigned 153 male patients to either intensive treatment (INT) (goal HbA(1c) 7.1%) or to standard treatment (ST) (goal HbA(1c) 9.1%; P = 0.001), and data were obtained during a 2-year period. Mean duration of known diabetes was 8 years, mean age of the patients was 60 years, and patients were well matched at baseline. We obtained 3-h urine samples for each patient at baseline and annually and defined microalbuminuria as an albumin:creatinine ratio of 0.03-0.30. All patients were treated with insulin and received instructions regarding diet and exercise. Hypertension and dyslipidemia were treated with similar goals in each group. RESULTS: A total of 38% of patients had microalbuminuria at entry and were evenly assigned to both treatment groups. INT retarded the progression of microalbuminuria during the 2-year period: the changes in albumin:creatinine ratio from baseline to 2 years of INT versus ST were 0.045 vs. 0.141, respectively (P = 0.046). Retardation of progressive urinary albumin excretion was most pronounced in those patients who entered the study with microalbuminuria and were randomized to INT. Patients entering with microalbuminuria had a deterioration in creatinine clearance at 2 years regardless of the intensity of glycemic control. In the group entering without microalbuminuria, the subgroup receiving ST had a lower percentage of patients with a macrovascular event (17%) than the subgroup receiving INT (36%) (P = 0.03). Use of ACE inhibitors or calcium-channel blockers was similarly distributed among the groups. CONCLUSIONS: Intensive glycemic control retards microalbuminuria in patients who have had type 2 diabetes for several years but may not lessen the progressive deterioration of glomerular function. Increases in macrovascular event rates in the subgroup entering without albuminuria who received INT remain unexplained but could reflect early worsening, as observed with microvascular disease in the Diabetes Control and Complications Trial.
机译:目的:微量白蛋白尿可反映微血管并发症的进展,并可预测2型糖尿病的大血管疾病。在美国,患有2型糖尿病已有数年的患者,强化血糖控制对微量白蛋白尿的影响尚未得到评估。研究设计和方法:我们随机分配153名男性患者接受强化治疗(INT)(目标HbA(1c)7.1%)或标准治疗(ST)(目标HbA(1c)9.1%; P = 0.001),并收集数据是在2年内获得的。已知糖尿病的平均病程为8年,患者的平均年龄为60岁,并且患者在基线时匹配良好。我们在基线和每年获取每位患者的3小时尿液样本,并将微量白蛋白尿定义为白蛋白:肌酐比率为0.03-0.30。所有患者均接受胰岛素治疗,并接受有关饮食和运动的指导。每组高血压和血脂异常的治疗目标相似。结果:共有38%的患者在入院时有微量白蛋白尿,并平均分配至两个治疗组。 INT在2年内延迟了微量白蛋白尿的进展:从基线到INT与ST的2年间白蛋白:肌酐比值的变化分别为0.045和0.141(P = 0.046)。在那些接受微量白蛋白尿并随机分配至INT的患者中,进行性尿白蛋白排泄的迟缓最为明显。不论血糖控制强度如何,进入微量白蛋白尿的患者在2年时肌酐清除率均下降。在没有微量白蛋白尿的组中,接受ST的亚组发生大血管事件的患者百分比(17%)低于接受INT的亚组(36%)(P = 0.03)。 ACE抑制剂或钙通道阻滞剂的使用在各组中的分布相似。结论:强化血糖控制可延迟患有2型糖尿病多年的患者的微量白蛋白尿,但不能减轻肾小球功能的逐步恶化。如在糖尿病控制和并发症试验中观察到的微血管疾病所观察到的,未接受白蛋白尿而接受INT的亚组进入大血管事件发生率的增加仍无法解释,但可能反映了早期恶化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号